119 related articles for article (PubMed ID: 16956486)
1. Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study.
Berman S; Quick R; Yoder P; Voigt S; Strootman D; Wade M
Vascular; 2006; 14(3):142-8. PubMed ID: 16956486
[TBL] [Abstract][Full Text] [Related]
2. The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia.
Belch JJ; Ray S; Rajput-Ray M; Engeset J; Fagrell B; Lepäntalo M; McKay A; Mackay IR; Ostergren J; Ruckley CV; Salenius J
Int Angiol; 2011 Apr; 30(2):150-5. PubMed ID: 21427652
[TBL] [Abstract][Full Text] [Related]
3. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
4. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
5. Treprostinil sodium Pharmacia.
Chattaraj SC
Curr Opin Investig Drugs; 2002 Apr; 3(4):582-6. PubMed ID: 12090728
[TBL] [Abstract][Full Text] [Related]
6. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ
Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868
[TBL] [Abstract][Full Text] [Related]
9. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.
Brass EP; Anthony R; Dormandy J; Hiatt WR; Jiao J; Nakanishi A; McNamara T; Nehler M;
J Vasc Surg; 2006 Apr; 43(4):752-9. PubMed ID: 16616232
[TBL] [Abstract][Full Text] [Related]
10. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
[TBL] [Abstract][Full Text] [Related]
11. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
Jones A; Wang-Smith L; Pham T; Laliberte K
J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
[TBL] [Abstract][Full Text] [Related]
14. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
[TBL] [Abstract][Full Text] [Related]
15. Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients.
Libri V; Gibbs JS; Pinato DJ; Iddamalgoda T; Khengar RH; Gin-Sing W; Huson L; Anand P
Br J Anaesth; 2014 Feb; 112(2):337-47. PubMed ID: 24062200
[TBL] [Abstract][Full Text] [Related]
16. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
[TBL] [Abstract][Full Text] [Related]
17. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
18. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization.
Marston WA; Davies SW; Armstrong B; Farber MA; Mendes RC; Fulton JJ; Keagy BA
J Vasc Surg; 2006 Jul; 44(1):108-114. PubMed ID: 16828434
[TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Simonneau G; Barst RJ; Galie N; Naeije R; Rich S; Bourge RC; Keogh A; Oudiz R; Frost A; Blackburn SD; Crow JW; Rubin LJ;
Am J Respir Crit Care Med; 2002 Mar; 165(6):800-4. PubMed ID: 11897647
[TBL] [Abstract][Full Text] [Related]
20. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.
Powell RJ; Simons M; Mendelsohn FO; Daniel G; Henry TD; Koga M; Morishita R; Annex BH
Circulation; 2008 Jul; 118(1):58-65. PubMed ID: 18559703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
